SPONSOR
GV20 Therapeutics
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2
Conditions studied: Solid Tumor, AdultRefractory CancerEndometrial Carcinoma (EC)Squamous Head and Neck CarcinomapMMR/MSS Adenocarcinoma of the Colon or RectumCutaneous MelanomaNon-Small Cell Lung CancerSolid Tumor CancerAdult Refractory CancerMelanoma
GV20 Therapeutics is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma.
The trial portfolio spans Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — GV20 Therapeutics
How many clinical trials has GV20 Therapeutics sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by GV20 Therapeutics, of which 2 are actively recruiting participants. These trials cover conditions including Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC). Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does GV20 Therapeutics research focus on?
GV20 Therapeutics clinical trials span Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum, and additional conditions. The research pipeline includes Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a GV20 Therapeutics clinical trial?
To participate in a GV20 Therapeutics trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all GV20 Therapeutics trials with current recruitment status updated daily.
Clinical Trials by GV20 Therapeutics
NCT05669430 Phase 1, Phase 2
Recruiting
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Solid Tumor, Adult
NCT07070518 Phase 1, Phase 2
Recruiting
Study of GV20-0251 in Participants With Solid Tumor Malignancies
Solid Tumor Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology